BHP Group Limited

BHP

BHP Group Ltd. engages in the exploration, development, production and processing of iron ore, metallurgical coal and copper. The company is headquartered in Melbourne, Victoria and currently employs 37,908 full-time employees. The firm is a producer of commodities, including iron ore, copper, nickel, potash and metallurgical (steelmaking) coal. The company is focused on offering a range of resources, which provides copper for renewable energy; nickel for electric vehicles; potash for sustainable farming, and iron ore and metallurgical coal for the steel needed for global infrastructure and the energy transition. Its segments include Copper, Iron Ore, and Coal. Its Copper segment is engaged in mining of copper, silver, zinc, molybdenum, uranium, and gold. Its Iron Ore segment is engaged in mining of iron ore. Its Coal segment is engaged in mining of metallurgical coal and energy coal. The firm is also focused on operating Olympic Dam, Prominent Hill, and Carrapateena underground copper-gold mines in South Australia. The firm's operations are situated in Australia, Europe, China, Japan, India, South Korea, rest of Asia, North America and South America.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The firm also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis and acne respectively. The company is also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.

Core Lithium Ltd

CXO

Core Lithium Ltd. is an Australian based mineral exploration company, which engages in the acquisition, exploration, evaluation, and development of copper, gold, uranium, and iron ore properties. The company is headquartered in Adelaide, South Australia. The company went IPO on 2011-02-11. The firm owns and operates Finniss Lithium project, which is located south of Darwin Port in the Northern Territory. The project lies within a prospective area for lithium in the NT, the Bynoe Pegmatite Field, and covers approximately 500 square kilometers (km2) of granted tenements. The project is approximately 88 kilometers (km) by sealed road from Darwin Port, Northern Territory. Its other projects include Shoobridge Lithium, Anningie and Barrow Creek Lithium, Sa Zinc, Jervois Domain, Blueys and Inkheart Lead/Silver, Bynoe Gold, Fitton Uranium, and Napperby Uranium. Shoobridge Lithium project is located approximately 80 km south-southeast of Finniss near Darwin in the Northern Territory. Sa Zinc project covers a total area of approximately 500 km2 in northern South Australia. Jervois Domain project covers three exploration licenses in the central Northern Territory.

CSL Limited

CSL

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 30,000 full-time employees. The Company’s areas of focus and exploration include rare and serious diseases, influenza vaccines, plasma collection, and therapies for iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment manufactures, markets, and distributes plasma therapies (plasma products and recombinants). CSL Seqirus segment manufactures, markets, and distributes primarily influenza-related products and provides pandemic services to governments. The Company’s CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency, dialysis and nephrology and rare diseases. The Company’s geographical areas of operation include Australia, the United States of America, Germany, the United Kingdom, Switzerland, and China. CSL’s products include HIZENTRA, PRIVIGEN, IDELVION, HAEMATE, KCENTRA, HAEGARDA, ZEMAIRA/RESPREEZA, FLUAD and FLUCELVAX.

Bannerman Energy Ltd

BMN

Bannerman Energy Ltd. engages in exploration and operation of uranium mining projects. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2005-04-28. The firm is focused on Etango Uranium Project located in the Erongo Region of Namibia, 30 kilometers (Km) south-east of Swakopmund. The firm holds uranium interests in Namibia. The company possesses a uranium mineral resource endowment of approximately 207 Mlbs of contained U3O8. Etango is an undeveloped uranium deposit. The firm is focused on the development of an open pit uranium operation at Etango. The Etango tenements possess a uranium mineral resource. The company has completed definitive feasibility study (DFS) and environmental permitting on the Etango Project. The firm constructed and operated a Heap Leach Demonstration Plant at Etango, which de-risked the acid heap leach process to be utilized on the Etango ore. Etango has de-risked through drilling, technical evaluation and operation of a process demonstration plant facility.